1. Home
  2. CTNM vs NMG Comparison

CTNM vs NMG Comparison

Compare CTNM & NMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • NMG
  • Stock Information
  • Founded
  • CTNM 2009
  • NMG 2011
  • Country
  • CTNM United States
  • NMG Canada
  • Employees
  • CTNM N/A
  • NMG N/A
  • Industry
  • CTNM
  • NMG Other Metals and Minerals
  • Sector
  • CTNM
  • NMG Basic Materials
  • Exchange
  • CTNM Nasdaq
  • NMG Nasdaq
  • Market Cap
  • CTNM 248.7M
  • NMG 297.2M
  • IPO Year
  • CTNM 2024
  • NMG 2017
  • Fundamental
  • Price
  • CTNM $12.40
  • NMG $2.30
  • Analyst Decision
  • CTNM Strong Buy
  • NMG Strong Buy
  • Analyst Count
  • CTNM 4
  • NMG 2
  • Target Price
  • CTNM $22.75
  • NMG $2.58
  • AVG Volume (30 Days)
  • CTNM 246.0K
  • NMG 53.7K
  • Earning Date
  • CTNM 11-05-2025
  • NMG 11-13-2025
  • Dividend Yield
  • CTNM N/A
  • NMG N/A
  • EPS Growth
  • CTNM N/A
  • NMG N/A
  • EPS
  • CTNM N/A
  • NMG N/A
  • Revenue
  • CTNM N/A
  • NMG N/A
  • Revenue This Year
  • CTNM N/A
  • NMG N/A
  • Revenue Next Year
  • CTNM N/A
  • NMG N/A
  • P/E Ratio
  • CTNM N/A
  • NMG N/A
  • Revenue Growth
  • CTNM N/A
  • NMG N/A
  • 52 Week Low
  • CTNM $3.35
  • NMG $1.22
  • 52 Week High
  • CTNM $20.30
  • NMG $2.58
  • Technical
  • Relative Strength Index (RSI)
  • CTNM 69.65
  • NMG 72.93
  • Support Level
  • CTNM $11.46
  • NMG $2.08
  • Resistance Level
  • CTNM $13.09
  • NMG $1.97
  • Average True Range (ATR)
  • CTNM 1.02
  • NMG 0.08
  • MACD
  • CTNM -0.07
  • NMG 0.03
  • Stochastic Oscillator
  • CTNM 74.89
  • NMG 94.32

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About NMG Nouveau Monde Graphite Inc.

Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The company currently operates in two segments: the Matawinie Mine Project and the Battery Material Plant project.

Share on Social Networks: